Biotechnology

Insmed

Insmed CEO William Lewis Sells $2.72M Stock and Exercises Options

Insmed's New Drug BRINSUPRI Sales Surge 44%, CEO Lewis Reaffirms Growth Confidence

FactSet: Insmed Inc 2026 EPS forecast median revised down to -2.5 USD

Insmed released FY2026 Q1 earnings on May 7 Pre-Market (EST), actual revenue USD 305.96 M (forecast USD 300.8 M), actual EPS USD -0.76 (forecast USD -0.9804)

Insmed CEO William Lewis Sells 10,699 Shares of Company Stock

Insmed to Present Respiratory Disease Research Abstracts at ATS International Conference in 2026

Wealthfront Advisers LLC Increases Stake in Insmed, Inc.

Insmed to Release FY2026 Q1 Earnings on May 7 Pre-Market EST, Forecast Revenue USD 299.04 M, EPS USD -0.9375

FactSet: Analysts Lower 2026 EPS Forecast for Insmed Inc

Analysts 上调 Insmed Inc 2026 年 EPS 预估

Insmed's brensocatib Fails in 2b Phase Trial for Adenitis Abscesses

Insmed's COO Roger Adsett Reduces Stock Holdings

Barclays Raises Insmed's Target Price to $237

Insmed's Chief Legal Officer Exercised Stock Options and Sold Shares

Morgan Stanley Raises Insmed Rating, Shares Up

Mizuho Raises Insmed's Target Price, Leading to Stock Price Increase

Truist Financial Analyst Gives Insmed a Buy Rating

Insmed's ARIKAYCE Demonstrates Positive Results in 3b Phase Trial for MAC Lung Disease

Insmed CEO William Lewis Sells Common Stock

Insmed Inc.'s Chief Legal Officer Michael Alexander Smith Sold Common Stock

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

INSM

Insmed CEO Will Lewis expressed confidence in the launch of BRINSUPRI, despite investor concerns over discontinuation rates. Sales surged to $208 million, a 44% increase. Lewis emphasized that discontinuation is just one metric and highlighted strong physician engagement and market growth potential. He noted that 25% of pulmonologists have prescribed the drug, with a focus on expanding prescriber usage. Insmed maintains its guidance for patient additions and is optimistic about its TPIP program as a future growth driver.

Market Beat

Bank of America

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus

LABU

ARKG

Insmed shareholders approved the election of Elizabeth McKee Anderson and Clarissa Desjardins as directors, endorsed the 2025 executive compensation package, and ratified Ernst & Young as the independent auditor for 2026. The latest analyst rating for INSM stock is a Buy with a $185.00 price target, though Spark's AI Analyst rates it as Neutral due to financial challenges despite positive revenue guidance.

Tip Ranks

Direxion S&P Biotech Bull 3X

Health Care Select Sector SPDR

Proshares Ultra Nasdaq Biotech

VG Health

iShares Biotechnology ETF

Invesco Dorsey Wright Healthcare Momentum ETF

Ark Genomic Revolution ETF

Invesco Biotechnology & Genome ETF

First Trust NYSE Arca Biotech Index Fd

BNY Mellon Innovators ETF

SPDR S&P Biotech

VanEck Biotech ETF

Insmed Shareholders Approve Directors, Executive Pay and Auditor

SBIO

Insmed executives sold shares totaling over $3.2 million. CEO William Lewis sold 13,283 shares for $1.54 million, CFO Sara Bonstein sold 8,272 shares for $961,040, and COO Roger Adsett sold 5,837 shares for $678,142, all to cover tax obligations and broker fees. Post-transactions, Lewis holds 287,902 shares, Bonstein 71,486 shares, and Adsett 100,973 shares.

TradingView

ALPS Medical Breakthrough

iShares Global Healthcare

Insmed Insiders Sold Shares Worth Over $3.2M

Insmed rose 12.19%; AbbVie rose 2.86%, with a transaction volume of USD 713 million; Gilead Sciences rose 1.95%, with a transaction volume of USD 380 million; Regeneron Pharmaceuticals rose 1.16%, with a transaction volume of USD 367 million; Amgen rose 1.57%, with a market value of USD 180.7 billion

Price Alert

Abbvie

Gilead Sciences

Regeneron Pharma

Amgen

U.S. stock market update: Insmed up 12.19%! Analysts are optimistic, and active options trading boosts stock price rise

Insmed (NASDAQ:INSM) shares rose 7.2% to $111.40, despite a 75% drop in trading volume. Analysts have mixed sentiments; HC Wainwright raised Q2 2026 EPS estimates while lowering longer-term projections. Mizuho and Barclays increased target prices, with a consensus rating of "Buy" and a target price of $211.86. Insmed reported a quarterly EPS of ($0.76), beating estimates, with revenue up 229.7% year-over-year. Insider selling activity was noted, with significant shares sold by executives. The company has a market cap of $24.38 billion and a negative PE ratio of -19.58.

Insmed (NASDAQ:INSM) Shares Up 7.2%  - What's Next?

ADEA

BURL

Notable options trading activity was observed in Adeia Inc (ADEA), Burlington Stores Inc (BURL), and Insmed Inc (INSM) today. ADEA saw 13,720 contracts traded, representing 1.4 million shares, with significant volume in the $35 call option. BURL had 4,149 contracts, about 414,900 shares, with high activity in the $250 put option. INSM recorded 21,150 contracts, equating to 2.1 million shares, with notable trading in the $130 call option. This activity reflects a substantial percentage of their average daily trading volumes.

nasdaq

Adeia

Burlington Stores

S&P 500

Nasdaq

Notable Monday Option Activity: ADEA, BURL, INSM

Stifel Nicolaus analyst Stephen Willey has maintained a Buy rating on Insmed (INSM) with a price target of $200.00, while the stock closed at $101.35. Willey, who focuses on the Healthcare sector, has an average return of 9.7% and a success rate of 44.65%. Insmed has a Strong Buy consensus with a price target of $207.79, indicating a potential upside of 105.02%. Barclays also supports a Buy rating with a target of $237.00.

iShares US Pharma

Stifel Financial

Disc Medicine

Incyte

Barclays

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Stifel Nicolaus Remains a Buy on Insmed (INSM)

HUBS

Last week, several large-cap stocks faced significant selloffs due to weak earnings and analyst downgrades. Zoetis, Insmed, and HubSpot were among the top losers, with declines of 27.12%, 24.34%, and 16.11%, respectively. Other notable declines included CDW Corporation (-22.9%), Applied Optoelectronics (-20.9%), and Arista Networks (-20.5%). The overall trend reflected investor disappointment with companies failing to meet market expectations, leading to heavy selling across various sectors.

benzinga_article

Zoetis

HubSpot

Applied Optoelectronics

Westlake

Arista Networks

Coupang

Ubiquiti

Alcon

Zoetis, Insmed, And HubSpot Are Among Top 10 Large-Cap Losers Last Week (May 4-May 8): Are The Others In Your Portfolio?

Comerica Bank has significantly reduced its holdings in Insmed, Inc. by 95.5%, selling 154,467 shares in the fourth quarter, leaving it with 7,337 shares valued at approximately $1.28 million. Other hedge funds have also adjusted their positions in Insmed. The company's stock has seen fluctuations, with a recent trading price of $101.17. Insmed reported a quarterly EPS of -$0.76, surpassing estimates, and a revenue increase of 229.7% year-over-year. Analysts have mixed sentiments, with some lowering price targets but maintaining bullish ratings.

Comerica

Canadian Imperial Bank Comm

ROYAL BANK OF CANADA

SBI Holdings, Inc.

Wells Fargo

COMERICA INC 6.875 % DEP PFD SER B

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Comerica Bank Sells 154,467 Shares of Insmed, Inc. $INSM

Insmed(INSM.US)